- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07943130
Exploring the Interplay Between Maternal Stress, Human Milk, and Epigenetic Changes in Preterm Infant's Neurodevelopment (EMBRACE)
Preterm birth represents a major challenge in pediatric healthcare, as preterm infants are at increased risk of neonatal complications and long-term neurodevelopmental impairments. Several factors may contribute to these outcomes, including gestational age at birth, postnatal comorbidities, and the neonatal intensive care unit (NICU) environment. Furthermore, preterm birth and prolonged hospitalization may negatively affect maternal psychological well-being, increasing the risk of stress, anxiety, and depression. These conditions may influence maternal sensitivity and responsiveness, mother-infant interactions, and infant neurodevelopment.
Emerging evidence suggests that maternal mental health may affect infant neurodevelopment through both direct biological mechanisms, such as epigenetic regulation, and indirect pathways, including changes in breast milk composition. Cortisol, a stress-related hormone present in breast milk and saliva, may play a role in stress regulation and neurobehavioral development. In particular, the methylation of Long Interspersed Nuclear Element-1 (LINE-1 or L1), a mobile genetic element involved in genomic regulation, may be influenced by environmental factors and early maternal care. Preliminary findings indicate that preterm infants exhibit lower L1 promoter methylation levels at birth than term infants, while early maternal care may modulate these levels and support neurobehavioral development.
The EMBRACE study aims primarily to investigate the relationship between biological maternal stress, measured through salivary cortisol levels, and L1 promoter methylation in blood samples collected from preterm infants from birth to 12 months of corrected age. Secondary objectives include examining this relationship in buccal swab samples, assessing associations between maternal perceived stress, anxiety, and depression and infant L1 methylation, and investigating the relationship between maternal psychological and biological stress indicators and infant neurodevelopmental outcomes. The study will also explore associations between perceived maternal stress and cortisol concentrations in breast milk and saliva, as well as longitudinal changes in L1 methylation.
This is a non-pharmacological, observational cohort study conducted at the Neonatology and Neonatal Intensive Care Unit of the Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico in Milan, Italy. Participants will include preterm infants born between 24+0 and 30+6 weeks of gestational age and their mothers. Assessments will be conducted at five time points: birth, transition to intermediate care or 34 weeks of postmenstrual age, hospital discharge, 6 months, and 12 months of corrected age. Maternal assessments will include standardized questionnaires evaluating stress, anxiety, and depression, as well as cortisol measurements in saliva and breast milk. Infant assessments will include L1 methylation analyses in blood and buccal samples and standardized neurodevelopmental evaluations as part of routine clinical follow-up. No additional invasive procedures will be performed, as blood samples will be collected during routine clinical care.
The study is expected to improve understanding of the relationships between maternal stress, anxiety, depression, epigenetic regulation, and neurodevelopment in preterm infants. It will also investigate the potential role of breast milk cortisol in these associations. Ultimately, the findings may contribute to the development of early interventions aimed at improving neurodevelopmental outcomes in preterm infants and supporting maternal psychological well-being.
Descripción general del estudio
Estado
Condiciones
Tipo de estudio
Inscripción (Estimado)
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Camilla Fontana
- Número de teléfono: 0255032951
- Correo electrónico: camilla.fontana@unimi.it
Ubicaciones de estudio
-
-
Lombardy
-
Milan, Lombardy, Italia, 20122
- Reclutamiento
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
-
Contacto:
- Camilla Fontana
- Número de teléfono: +390255032951
- Correo electrónico: camilla.fontana@unimi.it
-
Sub-Investigador:
- Chiara Bonfanti
-
Sub-Investigador:
- Agnese De Carli
-
Sub-Investigador:
- Monica Fumagalli
-
Sub-Investigador:
- Mary Giorgia Gaccione
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
All preterm infants born at the SC Neonatologia e Terapia Intensiva Neonatale - Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milano and their mothers.
Descripción
Inclusion Criteria:
- Preterm infants born between 24+0 and 30+6 weeks of gestational age (GA);
- Mothers aged ≥ 18 years with adequate understanding of the Italian language;
- Signed informed consent from parents.
Exclusion Criteria:
- Parents decline participation;
- Infants with major congenital anomalies, malformations, or genetic syndromes;
- Mothers with obvious psychiatric conditions, cognitive deficits, or active substance abuse at the time of delivery.
- Infants birth samples not available (both buccal swab and blood)
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: COHORT
- Perspectivas temporales: PROSPECTIVE
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Epigenetic changes on LINE1 (blood samples)
Periodo de tiempo: up to 48 weeks post menstrual age
|
epigenetic analysis is performed on cord blood samples collected at birth, at transition to intermediate care and at hospital discharge on peripheral blood samples |
up to 48 weeks post menstrual age
|
|
Maternal salivary cortisol
Periodo de tiempo: up to 12 months corrected age of the infant
|
Collected at birth, transition to intermediate care, discharge |
up to 12 months corrected age of the infant
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Human milk cortisol concentrations
Periodo de tiempo: up to 6 months corrected age of the infant
|
Collected at birth, transition to intermediate care, discharge |
up to 6 months corrected age of the infant
|
|
Buccal swab
Periodo de tiempo: up to 12 months corrected age
|
Collected at birth, 34 weeks GA, discharge, 6 and 12 months corrected age |
up to 12 months corrected age
|
|
Neurological outcome
Periodo de tiempo: up to 44 weeks post menstrual age
|
Hammersmith neonatal neurological examination performed at NICU discharge |
up to 44 weeks post menstrual age
|
|
Neonatal Visual Assessment
Periodo de tiempo: up to 44 weeks post menstrual age
|
Neonatal visual function in assessed at discharge using the Visual Assessment battery developed by Ricci et al. The assessment has 9 items and each one is scored as normal or abnormal according to the description given by the authors. |
up to 44 weeks post menstrual age
|
|
Neonatal behavior
Periodo de tiempo: up to 44 weeks post menstrual age
|
Neonatal behavior is assessed using the Neonatal Behavior Assessment Scale, and in particular the areas of state organization, state regulation, and the autonomic system. Each item will be scored according to the description given by the author of the assessment |
up to 44 weeks post menstrual age
|
|
Neurodevelopmental outcome
Periodo de tiempo: from 6 to 12 months corrected age
|
Bayley scales to assess neurodevelopment at 6 and 12 months corrected age. The normal range for the composite score is 100 +/- 15 points. Higher scores mean better outcomes. |
from 6 to 12 months corrected age
|
|
Maternal depression
Periodo de tiempo: up to 12 months corrected age of the infant
|
Assessed with the Edinburgh Postnatal depression scale. Responses are scored 0 to 3. A score above 8 is considered pathological in the post partum period. It will be administered at birth, at transition to intermediate care, at NICu discharge at 6 and 12 months corrected age. |
up to 12 months corrected age of the infant
|
|
Maternal stress in the NICU
Periodo de tiempo: up to 12 months corrected age of the infant
|
Assessed with the Parental Stressor Scale: Neonatal Intensive Care Unit (PSS:NICU). It is composed of 35 items that are scored on a 5-point Likert scale ranging from 1 (not stressful at all) to 5 (extremely stressfull). It will be administered at birth, at transition to intermediate care and at NICu discharge. |
up to 12 months corrected age of the infant
|
|
Maternal bonding
Periodo de tiempo: up to 12 months corrected age of the infant
|
Assessed with the Postpartum Bonding Questionnaire (PBQ) administered at NICU discharge, 6 and 12 months corrected age. A score above 26 is considered pathological. |
up to 12 months corrected age of the infant
|
|
Maternal anxiety and depression
Periodo de tiempo: up to 12 months corrected age of the infant
|
Assessed with the hospital anxiety and depression scale (HAD-S). It will be administered at birth, at transition to intermediate care, at NICu discharge at 6 and 12 months corrected age. A score from 0 to 7 is normal, 8-10 borderline and 11-21 score in the clinical range. |
up to 12 months corrected age of the infant
|
|
Parenting stress
Periodo de tiempo: up to 12 months corrected age of the infant
|
Assessed with the Parenting Stress Index Scale. Administered at 6 and 12 months corrected age. It is composed of 36 items that are scored on a 5-point Likert scale ranging from 1 (not stressful at all) to 5 (extremely stressful) |
up to 12 months corrected age of the infant
|
Colaboradores e Investigadores
Colaboradores
Publicaciones y enlaces útiles
Publicaciones Generales
- Bedrosian TA, Quayle C, Novaresi N, Gage FH. Early life experience drives structural variation of neural genomes in mice. Science. 2018 Mar 23;359(6382):1395-1399. doi: 10.1126/science.aah3378.
- Pace CC, Spittle AJ, Molesworth CM, Lee KJ, Northam EA, Cheong JL, Davis PG, Doyle LW, Treyvaud K, Anderson PJ. Evolution of Depression and Anxiety Symptoms in Parents of Very Preterm Infants During the Newborn Period. JAMA Pediatr. 2016 Sep 1;170(9):863-70. doi: 10.1001/jamapediatrics.2016.0810.
- Fontana C, Marasca F, Provitera L, Mancinelli S, Pesenti N, Sinha S, Passera S, Abrignani S, Mosca F, Lodato S, Bodega B, Fumagalli M. Early maternal care restores LINE-1 methylation and enhances neurodevelopment in preterm infants. BMC Med. 2021 Feb 5;19(1):42. doi: 10.1186/s12916-020-01896-0.
- Casavant SG, Cong X, Moore J, Starkweather A. Associations between preterm infant stress, epigenetic alteration, telomere length and neurodevelopmental outcomes: A systematic review. Early Hum Dev. 2019 Apr;131:63-74. doi: 10.1016/j.earlhumdev.2019.03.003. Epub 2019 Mar 11.
- Rosen-Carole CB, Greenman S, Wang H, Sonawane S, Misra R, O'Connor T, Jarvinen K, D'Angio C, Young BE. Association between maternal stress and premature milk cortisol, milk IgA, and infant health: a cohort study. Front Nutr. 2024 Mar 6;11:1270523. doi: 10.3389/fnut.2024.1270523. eCollection 2024.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Otros números de identificación del estudio
- EMBRACE
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .